Drug Eluting Stents Market
The Global Drug Eluting Stents Market is estimated to be valued at USD 7.81 Bn in 2024 and is expected to reach USD 13.82 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031. The global drug eluting stents market has witnessed significant growth in the past few years owing to the rising prevalence of cardiovascular diseases and increasing geriatric population worldwide who are more prone to coronary heart diseases and artery blockages. Drug eluting stents are increasingly being preferred by physicians over bare metal stents due to advantages such as lower rates of restenosis. Moreover, technological advancements in design of stents and drugs coated on stent surfaces have improved clinical outcomes for patients. However, high costs of drug eluting stents compared to bare metal stents remain a major challenge for market growth.
Market Dynamics:
The global drug eluting stents market is driven by the rising geriatric population, growing burden of cardiovascular diseases, and advantages offered by drug eluting stents over bare metal stents such as lower restenosis rates. However, the high costs of drug eluting stents compared to bare metal stents can hamper the market growth. Various developments in stent technology and drug coatings are expected to present lucrative opportunities for market players. For example, bioabsorbable drug eluting stents that dissolve in the body after performing their action could witness increasing adoption. Likewise, development of stent surfaces that enhance binding of drug molecules could help reduce drug elution times and costs of treatment.
Key Features of the Study:
- This report provides in-depth analysis of the global drug eluting stents market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global drug eluting stents market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Abbott Laboratories, Boston Scientific Corporation, Medtronic, Terumo Corporation, B. Braun Melsungen AG, C. R. Bard Inc., Cook Medical Inc., Biotronik SE & Co. KG, MicroPort Scientific Corporation, St. Jude Medical (now part of Abbott), Johnson & Johnson, Cardiovascular Systems Inc., Gore Medical, InspireMD, Asahi Intecc Co., Ltd., and Z-Medica
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global drug eluting stents market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug eluting stents market
Market Segmentation
Market Segmentation
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
